Letairis, Volibris(ambrisentan)
Ambrisentan, Letairis, Volibris (ambrisentan) is a small molecule pharmaceutical. Ambrisentan was first approved as Letairis on 2007-06-15. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against endothelin-1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Ambrisentan, Letairis (discontinued: Ambrisentan)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ambrisentan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LETAIRIS | Gilead Sciences | N-022081 RX | 2007-06-15 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ambrisentan | ANDA | 2024-09-17 |
| letairis | New Drug Application | 2020-12-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | 11 | 18 | 11 | 10 | 51 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | 7 | 11 | 8 | 10 | 36 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 4 | 10 | 12 | 6 | 6 | 35 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | 1 | 7 | 6 | 6 | 20 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | 1 | — | 2 | 2 | 5 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 1 | — | 2 | 2 | 5 |
| Sclerosis | D012598 | — | — | — | 1 | — | 2 | 1 | 4 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | — | 1 | — | 3 |
| Univentricular heart | D000080039 | — | Q20.4 | — | 1 | — | 1 | — | 2 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fibrosis | D005355 | — | — | — | 1 | 2 | — | — | 3 |
| Covid-19 | D000086382 | — | — | — | 2 | 1 | — | — | 2 |
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | 1 | 1 | 1 | — | — | 2 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | 1 | — | 1 | 2 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | — | 2 | — | — | 2 |
| Pulmonary fibrosis | D011658 | — | — | — | — | 2 | — | — | 2 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 2 | — | — | — | 2 |
| Ascites | D001201 | HP_0001541 | R18 | — | 2 | — | — | — | 2 |
| Syndrome | D013577 | — | — | 1 | 1 | — | — | — | 2 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | — | 1 | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | 1 | — | — | — | 1 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 1 | — | — | — | 1 |
| Hypoplastic left heart syndrome | D018636 | — | Q23.4 | — | 1 | — | — | — | 1 |
| Dextrocardia | D003914 | HP_0001651 | Q24.0 | — | 1 | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
| Fatigue | D005221 | HP_0012378 | R53.83 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 1 | 1 |
| Ulcer | D014456 | MPATH_579 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ambrisentan |
| INN | ambrisentan |
| Description | Ambrisentan is a diarylmethane. |
| Classification | Small molecule |
| Drug class | endothelin receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 177036-94-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1111 |
| ChEBI ID | — |
| PubChem CID | 6918493 |
| DrugBank | DB06403 |
| UNII ID | HW6NV07QEC (ChemIDplus, GSRS) |
Target
Agency Approved
EDNRA
EDNRA
Organism
Homo sapiens
Gene name
EDNRA
Gene synonyms
ETA, ETRA
NCBI Gene ID
Protein name
endothelin-1 receptor
Protein synonyms
endothelin receptor subtype A, Endothelin receptor type A, endothelin-1-specific receptor, ET-A, ETA-R, G protein-coupled receptor, hET-AR
Uniprot ID
Mouse ortholog
Ednra (13617)
endothelin-1 receptor (Q91VV2)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Letairis – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,512 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ambrisentan, Letairis
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
107,319 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use